Apimeds boosts CEO salary to $500K and adds 24-month severance with equity vesting

Apimeds Pharmaceuticals US, Inc.

CEO Erik Emerson's annual base salary increased to $500,000, effective Nov 13, 2025.
If terminated without cause, Emerson gets 24 months salary/benefits plus immediate vesting of all unvested equity.
On termination for cause or voluntary quit without good reason, unvested equity forfeited automatically.
Amendment modifies the original Sept 21, 2023 employment agreement.

item 5.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.